Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of genetically engineered mice for lung cancer with mutant EGFR.

Biochemical and biophysical research communications - 3 Dec 2022

Kim Da-Som, Ji Wonjun, Kim Dong Ha, Choi Yun Jung, Im Kyungtaek, Lee Chae Won, Cho Jeongin, Min Joongkee, Woo Dong-Cheol, Choi Chang-Min, Lee Jae Cheol, Sung Young Hoon, Rho Jin Kyung

Abstract excerpt

Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown dramatic response and improvement in treating lung cancer with mutant EGFR, the emergence of drug resistance remains a major problem. In particular, some mutations including T790 M and C797S have been recognized as mechanisms of acquired resistance because they weaken binding affinity to drugs. To date, many attempts...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Luciferases, Firefly

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 36206598
DOI: 10.1016/j.bbrc.2022.09.104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of genetically engineered mice for lung cancer with mutant EGFR.PMID 36206598Read ↗

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.Semantic proximity Read ↗

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.Semantic proximity Read ↗

Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter.Semantic proximity Read ↗

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.Semantic proximity Read ↗

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.Semantic proximity Read ↗

EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.Semantic proximity Read ↗

Genetically-engineered mouse models of small cell lung cancer: the next generationSemantic proximity Read ↗

Versatile and enhanced tumour modelling in mice via somatic cell transduction.Semantic proximity Read ↗

“Non-viral CRISPR/Cas9 Mutagenesis for Streamlined Generation of Mouse Lung Cancer Models.”Semantic proximity Read ↗

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.Semantic proximity Read ↗

A Quantitative Volumetric Micro-Computed Tomography Method to Analyze Lung Tumors in Genetically Engineered Mouse ModelsSemantic proximity Read ↗

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.